SUN-392 Trends in Patients Hospitalized with Thyrotoxicosis in the US From 2010-2019

Abstract Disclosure: D. Cornejo Gonzalez: None. A. Vallejo: None. B. Mark: None. N. Krueger: None. E. Martinez Trevino: None. H. Shaka: None. Z. Aldeen: None. N. Al-Hashemi: None. K. Okonkwo: None. Introduction: Thyrotoxicosis is caused by an excess of circulating thyroid hormones, primarily due to inappropriately increased hormone production. The clinical presentation ranges from asymptomatic to life-threatening conditions such as thyroid storm. Recent trends in hospitalizations, costs, and mortality related to thyrotoxicosis have yet to be fully explored. This study aims to describe trends in incidence, mortality, length of stay (LOS), and demographic variables—including age, sex, and race—among patients hospitalized for thyrotoxicosis in the US over a recent 10-year period. Methods: A retrospective longitudinal analysis was conducted using data from the National Inpatient Sample (NIS) from 2010 to 2019, focusing on hospitalizations with thyrotoxicosis as the primary diagnosis. Trends analyzed included mortality rates, mean total costs, and LOS. Logistic regression was used to assess odds ratios (ORs) for mortality across variables such as year, age categories, sex, and race. Results: The annual number of hospitalizations decreased over the study period, while the mean total cost increased from $32,735 (95% CI: $28,291-$37,179) in 2010 to $44,556 (95% CI: $39,040-$50,073) in 2019. The mean LOS increased from 2.75 days (95% CI: 2.39-3.11) in 2010 to 3.26 days (95% CI: 2.86-3.66) in 2019. Mortality rates remained stable, with the mortality margin increasing from ∼0.86% in 2010 to ∼1.34% in 2019. Logistic regression revealed lower mortality odds for females (OR = 0.514, P < 0.001) compared to males and a significant increase in mortality risk with advancing age (e.g., OR = 3.48 for the oldest age category, P < 0.001). Conclusion: Over the 10-year period, the number of hospitalizations due to thyrotoxicosis decreased from 12,224 in 2010 to 8,765 in 2019. However, no significant difference in mortality was observed, highlighting potential areas for improvement in inpatient care. This trend aligns with other recent retrospective longitudinal studies [1]. Notably, we found a statistically significant decrease in the risk of death for female patients compared to males, while older patients faced a markedly increased risk. These findings underscore the need for targeted interventions to reduce costs and improve outcomes for high-risk populations. Lastly, total hospitalization costs adjusted for inflation have increased, possibly due to prolonged LOS. [1] Shaka H, Salim M, DeHart L, El-Amir Z, Wani F, Kichloo A. A decade of hospitalizations for hyperthyroidism in the US. Proc (Bayl Univ Med Cent). 2022 Aug 17;35(6):773-777. doi: 10.1080/08998280.2022.2106452. PMID: 36338261; PMCID: PMC9601540. Presentation: Sunday, July 13, 2025